Lab Notes: Endo acquires 6 product candidates for $35M; NiKang signs deal worth up to $218M
May 06, 2022 at 12:34 PM EDT
Marinus Pharmaceuticals resumes late-stage testing of its experimental seizure medication.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||